Zentalis Pharmaceuticals Inc (ZNTL)

$2.82 +0.31 (12.35%)
Market Cap 175.57M
Revenue (ttm) 67.43M
Net Income (ttm) -165.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -245.94%
Debt to Equity Ratio 0.00
Volume 1,127,000
Avg Vol 1,474,218
Day's Range N/A - N/A
Shares Out 72.25M
Stochastic %K 51%
Beta 1.75
Analysts Sell
Price Target $5.31

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 433 3791
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
lucabrix
lucabrix Feb. 3 at 9:58 PM
$ZNTL
0 · Reply
jtfr1189
jtfr1189 Feb. 3 at 9:14 PM
$ZNTL whoops
0 · Reply
Snackdaddy
Snackdaddy Feb. 2 at 9:01 PM
$ZNTL back to red tomorrow. needed a green day somewhere. still heading to $2 it seems
0 · Reply
lucabrix
lucabrix Feb. 2 at 4:01 PM
$ZNTL seems ready for a restart
1 · Reply
Snackdaddy
Snackdaddy Jan. 30 at 4:02 PM
$ZNTL been a great short at thid rate easily back under $2. close and buy around $1.8
0 · Reply
Snackdaddy
Snackdaddy Jan. 29 at 3:53 PM
$ZNTL was $4.60 now looking for bottom. probably sub $2. then maybe insiders will buy again to pump it up
0 · Reply
zawojak
zawojak Jan. 28 at 10:41 PM
$ZNTL Pump n dump stock, classic.
0 · Reply
Snackdaddy
Snackdaddy Jan. 28 at 7:31 PM
$ZNTL oof. sub $2 soon
0 · Reply
zawojak
zawojak Jan. 28 at 5:44 PM
$AQST $FIP $NUVB $ZNTL US markets performance in line with country performance - it is tanking daily 🥲
1 · Reply
Snackdaddy
Snackdaddy Jan. 28 at 3:20 PM
$ZNTL we going to slow dripnto $2 over the next month? would love to pick this up cheap for the end of year
0 · Reply
Latest News on ZNTL
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Feb 3, 2026, 4:05 PM EST - 6 hours ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Jan 6, 2026, 8:00 AM EST - 4 weeks ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Dec 9, 2025, 2:07 PM EST - 2 months ago

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 4:05 PM EST - 3 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 5:25 PM EST - 3 months ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 3, 2025, 8:15 AM EST - 3 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 4 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:27 PM EDT - 5 months ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Aug 26, 2025, 4:05 PM EDT - 5 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 5:00 PM EDT - 7 months ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 4:05 PM EDT - 9 months ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 4:05 PM EDT - 11 months ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 25, 2025, 4:40 PM EDT - 11 months ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 15, 2025, 11:25 AM EDT - 11 months ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 1 year ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 1 year ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 1 year ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

lucabrix
lucabrix Feb. 3 at 9:58 PM
$ZNTL
0 · Reply
jtfr1189
jtfr1189 Feb. 3 at 9:14 PM
$ZNTL whoops
0 · Reply
Snackdaddy
Snackdaddy Feb. 2 at 9:01 PM
$ZNTL back to red tomorrow. needed a green day somewhere. still heading to $2 it seems
0 · Reply
lucabrix
lucabrix Feb. 2 at 4:01 PM
$ZNTL seems ready for a restart
1 · Reply
Snackdaddy
Snackdaddy Jan. 30 at 4:02 PM
$ZNTL been a great short at thid rate easily back under $2. close and buy around $1.8
0 · Reply
Snackdaddy
Snackdaddy Jan. 29 at 3:53 PM
$ZNTL was $4.60 now looking for bottom. probably sub $2. then maybe insiders will buy again to pump it up
0 · Reply
zawojak
zawojak Jan. 28 at 10:41 PM
$ZNTL Pump n dump stock, classic.
0 · Reply
Snackdaddy
Snackdaddy Jan. 28 at 7:31 PM
$ZNTL oof. sub $2 soon
0 · Reply
zawojak
zawojak Jan. 28 at 5:44 PM
$AQST $FIP $NUVB $ZNTL US markets performance in line with country performance - it is tanking daily 🥲
1 · Reply
Snackdaddy
Snackdaddy Jan. 28 at 3:20 PM
$ZNTL we going to slow dripnto $2 over the next month? would love to pick this up cheap for the end of year
0 · Reply
John_week
John_week Jan. 23 at 8:16 PM
$ZNTL that’s it?
1 · Reply
Snackdaddy
Snackdaddy Jan. 23 at 8:04 PM
$ZNTL gave it all back. get used to this for months. play the pumps and short the dumps
0 · Reply
kshonstocks
kshonstocks Jan. 22 at 8:21 PM
$ZNTL looks like its trying to turn back up
0 · Reply
lucabrix
lucabrix Jan. 22 at 8:17 PM
$ZNTL getting steam for the next big run
2 · Reply
Alidrisi
Alidrisi Jan. 22 at 5:49 PM
$ZNTL
1 · Reply
amitadi
amitadi Jan. 21 at 8:00 PM
$ZNTL udrub ya kalb
0 · Reply
MACTEP
MACTEP Jan. 20 at 11:39 PM
$ZNTL Bloodbath incoming... Next target - $2
0 · Reply
Snackdaddy
Snackdaddy Jan. 20 at 7:24 PM
$ZNTL its looking for bottom. insiders bought $2.84
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 19 at 6:46 PM
$ZNTL RSI: 74.39, MACD: 0.5131 Vol: 0.94, MA20: 2.12, MA50: 1.67 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GSP
GSP Jan. 18 at 9:48 PM
I like this lower volume pullback in $ZNTL after a big run. I'll be watching for a long trade this week. .
1 · Reply
GSP
GSP Jan. 18 at 9:09 PM
$ZNTL
0 · Reply
Broview
Broview Jan. 17 at 8:36 AM
$ZNTL No WEE1 inhibitors are FDA-approved yet, with Zentalis most advanced?
0 · Reply